Company Overview of Synthetic Genomics, Inc.
Synthetic Genomics, Inc., a synthetic biology company, develops and commercializes genomic-driven solutions and products for various industries worldwide. The company focuses on various commercialization programs, including developing synthetic DNA products, tools, and instruments for organizations with demands for large and/or complex DNA constructs; algae based food and nutritional products, and biofuels; and synthetically-derived vaccines and anti-microbials. It also develops clean water technologies using microbial fuel cells; and sustainable agricultural products. Synthetic Genomics, Inc. was formerly known as Synthetic Genomic Solutions, Inc. The company was founded in 2005 and is base...
11149 North Torrey Pines Road
La Jolla, CA 92037
Founded in 2005
Key Executives for Synthetic Genomics, Inc.
Chief Executive Officer and Director
Co-Founder, Executive Chairman and Co-Chief Scientific Officer
Co-Founder, Co-Chief Scientific Officer and Director
Co-Founder, Executive Vice President, General Counsel and Director
Co-Founder, Chief Business Officer and Director
Compensation as of Fiscal Year 2015.
Synthetic Genomics, Inc. Key Developments
Synthetic Genomics Expands Multi-Year Research and Development Agreement with Lung Biotechnology PBC
Sep 24 15
Synthetic Genomics has expanded its multi-year research and development agreement with Lung Biotechnology PBC. The contract has been signed to develop transplantation-ready pig organs using synthetic genomic advances. Both firms initially focused efforts on lung diseases and will now also include kidney diseases. Under the contract, SGI will receive royalties and milestones from the development and commercialization of the organs.
Synthetic Genomics, Inc. Presents at World Congress on Industrial Biotechnology, Jul-22-2015 08:30 AM
Jul 16 15
Synthetic Genomics, Inc. Presents at World Congress on Industrial Biotechnology, Jul-22-2015 08:30 AM. Venue: Palais des congrès de Montréal, Montréal, Quebec, Canada. Speakers: Thomas Ishoey, Vice President of Product & Technology Development.
Synthetic Genomics, Inc. and Gen9 Sign Licensing Agreement for Synthetic Biology Technology Patents
Jun 11 15
Synthetic Genomics, Inc. and Gen9 Inc. announced a strategic licensing agreement to leverage their respective strengths in synthetic biology technology development and commercialization. The agreement provides Gen9 Inc. with a non-exclusive worldwide license to SGI's Febit intellectual property estate. The financial details of the agreement were not disclosed.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 22, 2015
Most Searched Private Companies
Sponsored Financial Commentaries